Poxel S.A. (PXXLF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Poxel S.A. (PXXLF) with AI Score 66/100 (Buy). Poxel S. A. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases, particularly type 2 diabetes and liver diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Poxel S.A. (PXXLF) Healthcare & Pipeline Overview
Poxel S.A., a French clinical-stage biopharmaceutical company, specializes in developing innovative therapies for metabolic diseases, including type 2 diabetes and NASH, with its lead drug candidate Imeglimin advancing through clinical trials and strategic partnerships driving future growth in the competitive biotechnology landscape.
Investment Thesis
Poxel S.A. presents a compelling, albeit high-risk, investment opportunity within the biotechnology sector. The primary value driver is Imeglimin, which has completed Phase III trials and targets a large market in type 2 diabetes. Successful commercialization, potentially through partnerships, could generate significant revenue. PXL770 and other pipeline assets represent further upside potential, particularly in the NASH market. However, the company's negative profit margin of -178.5% and reliance on future clinical trial success pose substantial risks. Upcoming clinical trial results and potential partnership agreements are key catalysts to watch in 2026.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion, reflecting its status as a small-cap biopharmaceutical company.
- P/E ratio of -0.91, indicating the company is currently not profitable.
- Gross margin of 51.6%, suggesting strong potential profitability if revenues increase.
- Beta of 2.23, indicating a high level of volatility compared to the overall market.
- Lead product candidate Imeglimin has completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes.
Competitors & Peers
Strengths
- Novel drug candidates with unique mechanisms of action.
- Strategic partnerships with established pharmaceutical companies.
- Experienced management team with expertise in drug development.
- Positive clinical trial data for Imeglimin.
Weaknesses
- Limited financial resources.
- Reliance on future clinical trial success.
- High cash burn rate.
- Small number of employees.
Catalysts
- Upcoming: Results from Phase 2a clinical trial of PXL770 for NASH.
- Upcoming: Potential partnership agreements for Imeglimin commercialization.
- Ongoing: Regulatory approvals for Imeglimin in the United States and Europe.
- Ongoing: Advancement of PXL007 (EYP001) through Phase II study for hepatitis B and NASH.
- Ongoing: Progress in Phase I clinical trial of PXL065 for NASH.
Risks
- Potential: Clinical trial failures for pipeline assets.
- Potential: Regulatory delays or rejection of drug candidates.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and high cash burn rate.
- Ongoing: Dependence on strategic partnerships for commercialization.
Growth Opportunities
- Growth opportunity 1: Imeglimin's commercialization in Japan and potential launches in the United States and Europe represent a significant growth opportunity. The type 2 diabetes market is vast, and Imeglimin's unique mechanism of action could capture a substantial share. Successful partnerships with larger pharmaceutical companies will be crucial for maximizing market penetration and revenue generation. This opportunity has an ongoing timeline, dependent on regulatory approvals and commercial agreements.
- Growth opportunity 2: Development and commercialization of PXL770 for NASH represents another key growth driver. The NASH market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of the disease. Positive Phase 2a clinical trial results could attract partnerships and accelerate development. This opportunity is ongoing, with Phase 2a results expected to be a catalyst.
- Growth opportunity 3: Advancing PXL007 (EYP001) through its Phase II study for the treatment of hepatitis B and NASH, in partnership with Enyo Pharma S.A.S., offers a potential expansion of Poxel's therapeutic pipeline. Success in these trials could lead to further collaborations and licensing opportunities. The hepatitis B and NASH markets are substantial, presenting significant revenue potential. This is an ongoing opportunity tied to clinical trial progress.
- Growth opportunity 4: The development of PXL065, a mitochondrial pyruvate carrier inhibitor, for the treatment of NASH represents a longer-term growth opportunity. Positive results from the Phase I clinical trial could lead to further development and potential commercialization. The NASH market is rapidly growing, and PXL065 could address a significant unmet need. This opportunity is in its early stages, with a multi-year timeline.
- Growth opportunity 5: Strategic partnerships and licensing agreements represent a crucial growth strategy for Poxel. Collaborating with larger pharmaceutical companies can provide access to resources, expertise, and distribution networks, accelerating the development and commercialization of its pipeline assets. Successful partnerships can also generate upfront payments, milestone payments, and royalties, providing significant financial benefits. This is an ongoing strategy, with potential for new partnerships in the coming years.
Opportunities
- Commercialization of Imeglimin in key markets.
- Development and commercialization of PXL770 for NASH.
- Expansion of pipeline through strategic partnerships.
- Growing market for type 2 diabetes and liver disease treatments.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Economic downturn and reduced healthcare spending.
Competitive Advantages
- Novel drug candidates with unique mechanisms of action.
- Intellectual property protection for its pipeline assets.
- Strategic partnerships with established pharmaceutical companies.
- Clinical trial data demonstrating efficacy and safety.
About PXXLF
Poxel S.A., founded in 2009 and headquartered in Lyon, France, is a biopharmaceutical company dedicated to developing innovative treatments for metabolic diseases, with a primary focus on type 2 diabetes and liver diseases. The company's lead product candidate, Imeglimin, represents a novel approach to treating type 2 diabetes by improving pancreatic beta cell function, reducing insulin resistance, and addressing cardiovascular and metabolic risk factors. Imeglimin has completed Phase III clinical development in Japan and is also in Phase III trials in the United States and Europe. Poxel is also developing PXL770, an adenosine monophosphate-activated protein kinase (AMPK) activator, currently in a Phase 2a clinical trial for chronic metabolic diseases, including non-alcoholic steatohepatitis (NASH). Additionally, Poxel has established strategic licensing agreements to expand its pipeline. These include a collaboration with Enyo Pharma S.A.S. for PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist in Phase II study for hepatitis B and NASH, and with DeuteRx LLC for PXL065, a mitochondrial pyruvate carrier (MPC) inhibitor in Phase I clinical trial for NASH. Poxel's strategy involves both internal development and external collaborations to address unmet medical needs in metabolic diseases and liver diseases.
What They Do
- Develop novel treatments for metabolic diseases.
- Focus on type 2 diabetes and liver diseases.
- Advance Imeglimin, an oral drug candidate, through clinical trials.
- Develop PXL770, an AMPK activator, for chronic metabolic diseases.
- Collaborate with Enyo Pharma S.A.S. for PXL007 (EYP001) in hepatitis B and NASH.
- Partner with DeuteRx LLC for PXL065 in NASH.
Business Model
- Develop and out-license novel drug candidates.
- Generate revenue through licensing agreements, milestone payments, and royalties.
- Focus on clinical development and regulatory approvals.
- Partner with larger pharmaceutical companies for commercialization.
Industry Context
Poxel S.A. operates in the highly competitive biotechnology industry, focusing on metabolic and liver diseases. The market for type 2 diabetes treatments is substantial and growing, driven by increasing prevalence rates globally. The NASH market is also expanding rapidly, with limited approved therapies creating significant opportunities for companies like Poxel. Competition includes established pharmaceutical companies and other biotech firms developing novel treatments for these conditions. Success hinges on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.
Key Customers
- Pharmaceutical companies seeking to license novel drug candidates.
- Patients with type 2 diabetes and liver diseases.
- Healthcare providers treating metabolic diseases.
Financials
Chart & Info
Poxel S.A. (PXXLF) stock price: Price data unavailable
Latest News
-
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
businesswire.com · Feb 16, 2026
-
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
businesswire.com · Feb 3, 2026
-
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
businesswire.com · Jan 30, 2026
-
Stocks That Hit 52-Week Highs On Friday
· Dec 27, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PXXLF.
Price Targets
Wall Street price target analysis for PXXLF.
MoonshotScore
What does this score mean?
The MoonshotScore rates PXXLF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
Poxel Announces the Implementation of an Equity Line With IRIS Capital as Part of the Execution of the Recovery Plan
POXEL SA: The Commercial Court of Lyon Approves the Recovery Plan and Brings an End to the Judicial Reorganisation Proceedings
Stocks That Hit 52-Week Highs On Friday
Leadership: Nicolas Trouche
CEO
Nicolas Trouche serves as the CEO of Poxel S.A. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and financial management. He has held leadership positions in various companies, contributing to their growth and strategic direction. His expertise spans across multiple therapeutic areas, including metabolic diseases and liver diseases. He is responsible for overseeing Poxel's overall operations and driving its strategic initiatives.
Track Record: Under Nicolas Trouche's leadership, Poxel S.A. has achieved significant milestones, including the completion of Phase III clinical development for Imeglimin and the advancement of its pipeline assets. He has also been instrumental in securing strategic partnerships and licensing agreements, expanding the company's reach and potential. His focus on innovation and strategic execution has positioned Poxel for future growth and success.
PXXLF OTC Market Information
Poxel S.A. trades on the OTC Other tier, which represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of exchanges like the NYSE or NASDAQ. This tier is generally associated with higher risk and less liquidity compared to higher-tiered OTCQX or OTCQB markets, or listed exchanges. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud or mismanagement compared to exchange-listed companies.
- OTC Other tier companies may not meet minimum listing requirements.
- Potential for delisting or trading suspension.
- Verify the company's registration and regulatory filings.
- Review available financial statements and audit reports.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with OTC trading.
- Consult with a financial advisor.
- Research the company's history and any past legal issues.
- Established partnerships with reputable pharmaceutical companies.
- Advancement of drug candidates through clinical trials.
- Intellectual property protection for its pipeline assets.
- Experienced management team with expertise in drug development.
- Headquartered in France, a country with strong regulatory oversight.
PXXLF Healthcare Stock FAQ
What does Poxel S.A. do?
Poxel S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for metabolic diseases, particularly type 2 diabetes and liver diseases. Its lead product candidate, Imeglimin, is an oral drug designed to improve pancreatic beta cell function and reduce insulin resistance, currently in Phase III clinical development. The company also develops other drug candidates, such as PXL770 for NASH, and collaborates with other companies to expand its pipeline.
What do analysts say about PXXLF stock?
AI analysis is pending for PXXLF, so there is no current analyst consensus available. Key valuation metrics include a market capitalization of $0.01 billion and a P/E ratio of -0.91, reflecting its current lack of profitability. Growth considerations center on the successful commercialization of Imeglimin and the advancement of its other pipeline assets. Investors should conduct their own due diligence before making any investment decisions.
What are the main risks for PXXLF?
The main risks for Poxel S.A. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's limited financial resources and high cash burn rate also pose significant risks. Additionally, its reliance on strategic partnerships for commercialization could be a vulnerability if these partnerships do not materialize or are not successful. Investing in clinical-stage biopharmaceutical companies carries inherent risks.
What are the key factors to evaluate for PXXLF?
Poxel S.A. (PXXLF) currently holds an AI score of 66/100, indicating moderate score. Key strength: Novel drug candidates with unique mechanisms of action.. Primary risk to monitor: Potential: Clinical trial failures for pipeline assets.. This is not financial advice.
How frequently does PXXLF data refresh on this page?
PXXLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PXXLF's recent stock price performance?
Recent price movement in Poxel S.A. (PXXLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidates with unique mechanisms of action.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PXXLF overvalued or undervalued right now?
Determining whether Poxel S.A. (PXXLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PXXLF?
Before investing in Poxel S.A. (PXXLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-15.
- AI analysis pending may provide further insights.